Skip to main content
. 2016 Aug 2;12(4):2664–2673. doi: 10.3892/ol.2016.4932

Table V.

Association between GLI1 and SMO expression and clinicopathological characteristics.

GLI1 SMO


Characteristics Patients, n (%) IOD (mean ± SD) P-value IOD (mean ± SD) P-value
Pathological stagea
  Well/moderately differentiated 47 (67.14) (1.18±0.94)×105 0.022b (1.78±1.05)×105 0.322
  Poorly differentiated 19 (27.14) (1.77±0.90)×105 (2.10±1.36)×105
Invasive extentc
  Stage 1 22 (31.43) (8.89±6.87)×104 0.005d (2.40±1.51)×105   0.019d
  Stage 2 20 (28.57) (1.33±0.53)×105 (1.26±0.55)×105
  Stage 3 28 (40.00) (1.69±1.20)×105 (1.91±0.92)×105
Lymph node statuse
  N0 44 (62.86) (1.15±0.73)×105 0.017b (1.92±1.26)×105 0.853
  N1 24 (34.29) (1.72±1.20)×105 (1.87±0.95)×105
Age, years
  ≤40 20 (28.57) (1.25±0.89)×105 0.981f (1.90±1.33)×105   0.747f
  41–56 41(58.57) (1.36±1.01)×105 0.783g (1.80±1.11)×105   0.567g
  ≥56   9 (12.86) (1.42±0.84)×105 0.788h (2.17±0.90)×105   0.389h
a

Pathological stage was undetermined in 4 patients.

b

Independent samples t-test.

c

According to the American Joint Committee on Cancer classification.

d

Unequal variance, Kruskal-Wallis test.

e

Lymph node status was undetermined in 2 patients. Equal variance, Fisher's least significant difference test:

f

patients in the ≤40-year-old group compared with patients in the 41–56-year-old group

g

patients in the 41–56-year-old compared with patients in the ≥56-year-old group

h

patients in the ≤40-year-old group compared with patients in the ≥56-year-old group. GLI1, glioma-associated oncogene 1; SMO, smoothened; IOD, integrated optical density; SD, standard deviation.